Pharmaceutical Company | The Truth About Skin Care

{ Tag Archives } Pharmaceutical Company

Lytix Biopharma AS Announces Approval By Hungarian Authorities To Start Phase IIa Clinical Trial With LytixarTM In Gram Positive Skin Infections

Main Category: Dermatology
Also Included In: Clinical Trials / Drug Trials; Infectious Diseases / Bacteria / Viruses
Article Date: 01 Sep 2010 – 6:00 PDT

email to a friend printer friendly opinions
<!– rate article
The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval in Hungary to commence a Phase IIa [...]

Also tagged Biopharma, Broad Spectrum, Clinical Trial, Clinical Trials, Cross Resistance, Drug Resistant Bacteria, Gram Positive Bacteria, Gunnar, Hungarian Authorities, Infectious Diseases, Mechanism Of Action, Novel Drug, Patient Group, Phase Iia, Rate Article, Regulatory Authorities, Resistant Staphylococcus Aureus, Skin Bacteria, Skin Infections

2010 09 01 Skin Care News Comments Off

Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis

Specialty pharmaceutical company LEO Pharma announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105)…

Also tagged Actinic Keratosis, American Academy, Annual Meeting, Cursor, Leo Pharma, Phase Iii, Skin Cancer, Skin Lesions

2010 03 06 Skin Care News Comments Off

Onset Therapeutics Announces Results Of BenzEFoam™ Skin Hydration Study

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced positive results from a skin moisturization study that compared the Company’s recently launched BenzEFoam™ (benzoyl peroxide 5.3%) Emollient Foam to a market leading combination gel containing clindamycin 1% – benzoyl peroxide 5%…

Also tagged Benzoyl Peroxide, Clindamycin, Onset Therapeutics, Skin Hydration, Skin Study

2009 12 17 Skin Care News Comments Off

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces that its most advanced oral antibacterial NXL103 (flopristin/linopristin), has started a Phase II clinical trial in adults with acute bacterial skin and skin structure infections (ABSSSI).

Also tagged Adults, Antibacterial, Bacterial Infections, Clinical Trial, Discovery, Global Problem, Microbial Resistance, Novel Antibiotics, Oral, Phase Ii, Skin And Skin, Skin Infections, Skin Structure Infections

2009 11 07 Skin Care News Comments Off

Merz Pharmaceuticals’ Belotero(R) Balance PMA Filing Formally Accepted For Review By The FDA

Merz Pharmaceuticals, LLC, a leading specialty pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has accepted for review Merz’s premarket approval (PMA) application for Belotero(R) Balance. Belotero(R) Balance is a hyaluronic acid based monophasic gel dermal filler that utilizes a cohesive polydensified matrix (CPM(TM)) technology.

Also tagged Company Announced That, Dermal Filler, Fda, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Hyaluronic Acid, Llc, Matrix, Merz Pharmaceuticals, Premarket Approval

2009 09 16 Skin Care News Comments Off

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, announced the FDA approval and commercial launch of HYLATOPIC™ Emollient Foam, a unique, non-steroidal prescription product indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including atopic dermatitis, allergic contact dermatitis and radiation dermatitis.

Also tagged Allergic Contact Dermatitis, Atopic Dermatitis, Contact Dermatitis, Dermatitis, Dermatoses, Fda, Fda Approval, Launch, Onset Therapeutics, Prescription Product, Radiation

2009 07 16 Skin Care News Comments Off

Taro Receives FDA Approval For Sulfacetamide Sodium Topical Suspension ANDA

Taro Pharmaceutical Industries Ltd. (”Taro,” the “Company,” Pink Sheets: TAROF) reported that its Canadian manufacturing site has received approval from the U.S. Food and Drug Administration (”FDA”) for its Abbreviated New Drug Application (”ANDA”) for Sulfacetamide Sodium Topical Suspension USP, 10% (lotion) (”sulfacetamide sodium lotion”).

Also tagged Abbreviated New Drug Application, Fda, Fda Approval, Food And Drug, Food And Drug Administration, Food And Drug Administration Fda, Pink Sheets, Sodium, Taro Pharmaceutical Industries, Taro Pharmaceutical Industries Ltd, Usp

2009 05 24 Skin Care News Comments Off

BioAlliance Pharma Presents Results On Its New Biotherapy Plasmid AMEP™ For Metastatic Melanoma At The American Association For Cancer Research

BioAlliance Pharma SA (Euronext Paris – BIO), a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has presented results on its new biotherapy, plasmid AMEP™, for metastatic melanoma treatment at the at the American Association for Cancer Research (AACR) 100th Annual Meeting, in Denver, April 18 to 22, 2009.

Also tagged Amep, American Cancer, Annual Meeting, Bioalliance, Biotherapy, Cancer Research Aacr, Euronext Paris, Hiv, Melanoma, Melanoma Treatment, Metastatic Melanoma, Opportunistic Infections, Pharma, Presents

2009 04 23 Skin Care News Comments Off

Ipsen: AZZALURE(R) Approved In The UK For Aesthetic Use In The Treatment Of Glabellar Lines

Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Paris:IPN), an international innovation-driven specialty pharmaceutical group, announced that Azzalure® (botulinum toxin Type A manufactured by Ipsen), a muscle relaxant specifically developed for aesthetic use, has recei

Also tagged Botulinum Toxin Type, Dermatology, Glabellar Lines, International Innovation, Ipn, Ipsen, Paris, Pharmaceutical Group

2009 03 13 Skin Care News Comments Off

Avidoxy(TM) DK, Simplifying Therapy For Millions Suffering From Severe Acne

Avidas(TM) Pharmaceuticals, a privately held, specialty pharmaceutical company which focuses on dermatology, women’s health and endocrinology, today announced the launch of Avidoxy(TM) DK (defence kit), a new patient convenience kit developed to control severe acne [...]

Also tagged Acne, Bacteria, Control, Convenience Kit, Endocrinology, Health, Launch, Patient Convenience, Pharmaceuticals, Severe Acne

2009 03 03 Skin Care News Comments Off

The Truth About Skin Care

{ Tag Archives } Pharmaceutical Company

Lytix Biopharma AS Announces Approval By Hungarian Authorities To Start Phase IIa Clinical Trial With LytixarTM In Gram Positive Skin Infections

Phase III REGION-I Study Shows PEP005 (ingenol Mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions In Patients With Actinic Keratosis

Onset Therapeutics Announces Results Of BenzEFoam™ Skin Hydration Study

Novexel Starts Phase II Clinical Trial With NXL103 In Adults With Acute Bacterial Skin And Skin Structure Infections (ABSSSI)

Merz Pharmaceuticals’ Belotero(R) Balance PMA Filing Formally Accepted For Review By The FDA

Onset Therapeutics Launches HYLATOPIC™ Emollient Foam For Atopic Dermatitis

Taro Receives FDA Approval For Sulfacetamide Sodium Topical Suspension ANDA

BioAlliance Pharma Presents Results On Its New Biotherapy Plasmid AMEP™ For Metastatic Melanoma At The American Association For Cancer Research

Ipsen: AZZALURE(R) Approved In The UK For Aesthetic Use In The Treatment Of Glabellar Lines

Avidoxy(TM) DK, Simplifying Therapy For Millions Suffering From Severe Acne

Home

Recommendations

Free Ebook

Latest News

Site Features

Get a free ebook valued at $8.95 when you sign up for our free Skincare Tips newsletter. The book The Truth About Skincare: How To Have Younger Looking Skin sells every day for $8.95 at Bargain Books Web. It's yours at no cost by immediate download when you sign up right now. You can unsubscribe any time, and the book is yours to keep.
Name:
Email: